Figure 6. Relationship between TP53 mutation status and likelihood of ICB therapy.

Only 29/190 (15.3%) TP53-mutated patients were treated with ICB, a significantly lower proportion compared to that of TP53 wild type patients 74/300 (24.7%). The Fisher’s exact test statistic yields a p-value of 0.0126. Since response to ICB was interrogated in these relationships, only the 490 treated patients were included in this analysis.